The treatment under Scheme 1 caused the significant increase in the number of Pgp+ cells in tumor: from 30% at baseline to 55.5 ± 1.5% after the 1st course and to 88.2 ± 1.5% after the 4th course of CHOP (Figure 3(b)). The gene discussed is DDIT3; the disease is neoplasm.